StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

Akari Therapeutics cash

Cash and short-term investments held at the end of each period.

Akari Therapeutics's cash was $7.69M at Jun 30, 2026. For fiscal 2025 it was $5.20M, up 95.7% from the year before. Over ten years it grew -22.8% a year on average. The highest annual figure on record is $69.06M in fiscal 2015.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.20M+95.7%
FY2024Dec 31, 2024$2.66M-30.8%
FY2023Dec 31, 2023$3.85M-71.0%
FY2022Dec 31, 2022$13.25M+41.5%
FY2021Dec 31, 2021$9.36M-33.4%
FY2020Dec 31, 2020$14.06M+145.2%
FY2019Dec 31, 2019$5.73M-4.0%
FY2018Dec 31, 2018$5.97M-78.9%
FY2017Dec 31, 2017$28.25M-36.2%
FY2016Dec 31, 2016$44.26M-35.9%
FY2015Dec 31, 2015$69.06M+1975.5%
FY2014Dec 31, 2014$3.33M+501.0%
FY2013Dec 31, 2013$553.65K-49.9%
FY2012Dec 31, 2012$1.10M+18300.0%
FY2011Dec 31, 2011$6.00K-33.3%
FY2010Dec 31, 2010$9.00K+200.0%
FY2009Dec 31, 2009$3.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.69M+183.8%
Q1 FY2026Mar 31, 2026$2.77M+7.2%
Q4 FY2025Dec 31, 2025$5.20M+95.7%
Q3 FY2025Sep 30, 2025$2.48M+10.6%
Q2 FY2025Jun 30, 2025$2.71M-35.1%
Q1 FY2025Mar 31, 2025$2.58M+97.1%
Q4 FY2024Dec 31, 2024$2.66M-30.8%
Q3 FY2024Sep 30, 2024$2.25M-52.5%
Q2 FY2024Jun 30, 2024$4.18M-41.8%
Q1 FY2024Mar 31, 2024$1.31M-88.7%
Q4 FY2023Dec 31, 2023$3.85M-71.0%
Q3 FY2023Sep 30, 2023$4.73M-42.0%
Q2 FY2023Jun 30, 2023$7.18M-23.3%
Q1 FY2023Mar 31, 2023$11.58M+205.5%
Q4 FY2022Dec 31, 2022$13.25M-5.7%
Q2 FY2022Jun 30, 2022$8.15M-33.8%
Q4 FY2021Dec 31, 2021$9.36M-26.6%
Q2 FY2021Jun 30, 2021$3.79M-51.5%
Q4 FY2020Dec 31, 2020$14.06M+145.2%
Q3 FY2020Sep 30, 2020$12.32M+96.5%
Q2 FY2020Jun 30, 2020$12.75M+365.8%
Q1 FY2020Mar 31, 2020$7.82M+27.3%
Q4 FY2019Dec 31, 2019$5.73M-4.0%
Q3 FY2019Sep 30, 2019$6.27M-59.8%
Q2 FY2019Jun 30, 2019$2.74M-90.3%
Q1 FY2019Mar 31, 2019$6.15M-79.6%
Q4 FY2018Dec 31, 2018$5.97M-86.5%
Q2 FY2018Jun 30, 2018$15.59M-72.0%
Q4 FY2017Dec 31, 2017$28.25M-54.0%
Q2 FY2017Jun 30, 2017$30.12M-56.4%
Q4 FY2016Dec 31, 2016$44.26M-43.8%
Q2 FY2016Jun 30, 2016$55.78M+27591.4%
Q1 FY2016Mar 31, 2016$61.43M+4523.4%
Q4 FY2015Dec 31, 2015$69.06M+1975.5%
Q3 FY2015Sep 30, 2015$78.77M+149618.5%
Q2 FY2015Jun 30, 2015$201.44K-98.2%
Q1 FY2015Mar 31, 2015$1.33M–
Q4 FY2014Dec 31, 2014$3.33M–
Q3 FY2014Sep 30, 2014$52.61K–
Q2 FY2014Jun 30, 2014$11.36M–

More Akari Therapeutics figures

See a number that looks wrong?